Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

4(57.1%)

Phase 2

2(28.6%)

Phase 1

1(14.3%)

7Total

Phase 3(4)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06029439Phase 3Recruiting

Study to Assess the Safety and Effectiveness of NMRA-335140-501

Role: lead

NCT06058013Phase 3Active Not Recruiting

Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Role: lead

NCT06058039Phase 3Active Not Recruiting

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

Role: lead

NCT06429722Phase 2Completed

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

Role: lead

NCT06029426Phase 3Completed

Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

Role: lead

NCT06546995Phase 1Completed

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

Role: lead

NCT04221230Phase 2Completed

Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo

Role: lead

All 7 trials loaded